Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dose-range exploration of sepantronium bromide in relapsed or refractory c-Myc-rearranged high-grade B-cell lymphoma
CTR20221648Phase 2Active
- Sponsor
- Createrna Science & Technology
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sepantronium in large-cell lymphoma, Burkitt lymphoma (BL), sponsored by Createrna Science & Technology. Started Jul 2022; status: active.
02
Drugs
sepantronium
03
Conditions
large-cell lymphomaBurkitt lymphoma (BL)
Beyond the preview
Go deeper on CTR20221648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221648.